Bing

Investors sold shares of Celgene (NASDAQ:CELG) on strength during trading on Wednesday, MarketBeat Ratings reports. $136.04 million flowed into the stock on the tick-up and $196.90 million flowed out of the stock on the tick-down, for a money net flow …
sleekmoney.com · 13 hours ago
Celgene
Celgene's shares have fallen around 20% since late July. The company didn't make any heads spin with its second-quarter earnings announced around the time the stock began its decline, but those results were solid.
The Motley Fool · ByKeith Speights · 6 hours ago
Biotech Stocks
NEW YORK ( TheStreet) -- Jim Cramer answered viewers' Twitter (TWTR) questions from the floor of the New York Stock Exchange, commenting on Qorvo (QRVO - Get Report), Celgene (CELG - Get Report) and Boston Scientific (BSX - Get Report), and on …
The Street · ByJim Cramer · 9/1/2015
Cramer
More from Bing News
... featured in the blog include the Amgen (AMGN), ARIAD (ARIA), Celgene (CELG), Amicus (FOLD) and Alnylam (ALNY). Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free. Here are highlights ...
Yahoo Finance · 8 hours ago
Analyst Blog
Celgene (NASDAQ:CELG)‘s stock had its “outperform” rating reissued by research analysts at William Blair in a research note issued on Friday, ARN reports. A number of other research analysts also recently …
Ticker Report · 8/28/2015
The firm set a “strong-buy” rating and a $160.00 price target on the biopharmaceutical company’s stock. Raymond James’ target price indicates a potential upside of 38.58% from the company’s current price. Shares of Celgene (NASDAQ:CELG ...
wkrb13.com · 1 day ago
Celgene’s second-quarter 2015 adjusted earnings and revenues were in line with expectations. The company expects adjusted earnings for 2015 in the range of $4.75–$4.85 per share (excluding stock-based …
Mideast Times · 8/21/2015
CELG) announced it has closed its acquisition of Receptos, Inc. Receptos stockholders received $232.00 per share in cash, for a total of approximately $7.2 billion, net of cash acquired. As a result of the completion of the merger, the common stock of ...
StreetInsider · 8/27/2015
Jim Cramer answered viewers' Twitter from the floor of the New York Stock Exchange, commenting on Qorvo (QRVO), Celgene (CELG), Boston Scientific (BSX), and on why September is a tough month on Wall Street. A viewer asked about Qorvo. Cramer …
11 Alive · 9/1/2015
Celgene Corporation (NASDAQ:CELG) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Receptos, Inc. at a price of $232.00 per share, net to the seller in cash, without interest and less required ...
Sip Trunking Report · 8/25/2015
Tender Offer

Celgene

Company
Celgene Corporation is an American biotechnology company that manufactures drug therapies for cancer and inflammatory disorders. I…
Celgene Corporation is an American biotechnology company that manufactures drug therapies for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company's major products are Thalomid, which is approved for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum, as well as in combination with dexamethasone for patients with newly diagnosed multiple myeloma, and Revlimid, for which the company has received FDA and EMA approval in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate …
Data from: Wikipedia